AFFF cancer lawsuit

AFFF Pollution and Rising Cancer Risk for Breastfeeding Women

Long-term health issues for newborns are raised by PFAS in drinking water derived from firefighting foam passed by breastfeeding

Friday, May 23, 2025 - Growing scientific knowledge of PFAS raises questions about whether widely found in aqueous film-forming foam (AFFF), these chemicals can transmit from exposed moms to their nursing infants. For decades military sites, airports, and fire departments have been extensively using AFFF to fight fuel-based flames. But AFFF's PFAS compounds are now well recognized to contaminate water and soil and last years long in the human body. PFAS has been found in drinking water supplies in towns close to former or active firefighting foam sites, which fuels worries about its transmission into breastmilk. Given that children are more susceptible to harmful exposures throughout early development, this idea really worries me. Studies now point to PFAS accumulating in mother tissues and being produced during breastfeeding, perhaps exposing nursing children to dangerous chemicals connected to cancer, immunological malfunction, and hormone disturbance. Some impacted families have sought guidance from an AFFF cancer attorney asking whether the diagnosis of a child or mother might be related to this exposure. Increasingly, AFFF cancer lawsuits draw attention to the potential of indirect transmission paths including nursing in addition to occupational or environmental contact. As stated by the United States, Environmental Protection Agency (EPA), PFAS can be discovered in blood tests of almost all Americans, and fresh evidence reveals it can even be detected in breastmilk of exposed individuals.

Particularly in areas with significant water contamination, emerging research has revealed that several PFAS chemicals can be transmitted from mother to child through breastfeeding. In one peer-reviewed study, moms living near known AFFF pollution sites had maximum levels of PFAS in breastfeeding, implying that bioaccumulation can occur even from low-level daily intake through drinking water. For newborns especially, whose growing organs and immune systems are more vulnerable to chemical disturbance, this is particularly troubling. Public health groups are pushing for more thorough PFAS testing and water filtration initiatives in impacted areas, even while health organizations still support nursing for its several advantages. Some studies contend that polluted populations should be given access to home filtration devices or bottled water free of PFAS and a top priority for federal remediation projects. There are no national recommendations for PFAS limits in breastmilk right now, which leaves doctors and moms in a challenging situation trying to evaluate risk. Growing scientific data fuels the demand for local and national governments to respond more forcefully. Legal professionals believe that future AFFF cancer claims would relate more and more to generational exposure, including cases involving newborns who subsequently acquire health issues perhaps linked to PFAS absorption during infancy. Long-term studies and increased health monitoring calls are getting louder as advocacy organizations seek more openness on AFFF use and how it affects nearby households.

The future shape of health policies and legal responsibility depends on ongoing studies on PFAS in breast milk. Stronger ties between AFFF exposure and newborn health outcomes could force legislators to approve tougher rules and actions for affected families. Legal systems could grow to cover more general groups of plaintiffs in AFFF cancer cases, including children exposed by maternal transfer.

Information provided by AFFFLawsuitCenter.com, a website devoted to providing news about AFFF and PFAS cancer, lymphoma and leukaemia claims, including a free no-cost, no-obligation AFFF Lawsuit Claim.

More Recent AFFF Lawsuit News:

View all AFFF Lawsuit News

No-Cost, No-Obligation Claim Review for Persons or Families of Persons Who Developed Cancer, Lymphoma or Leukaemia After Exposure to Firefighting Foam

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.


Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.